Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

PURPOSE: Ceritinib is an ALK receptor tyrosine kinase inhibitor approved as first- and second-line treatment in adult patients with ALK + metastatic non-small cell lung cancer (NSCLC). The study investigated the drug–drug interaction (DDI) potential of ceritinib when coadministered with midazolam an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurtado, Felipe K., de Braud, Filippo, De Castro Carpeño, Javier, de Miguel Luken, Maria Jose, Wang, Ding, Scott, Jeffrey, Lau, Yvonne Y., McCulloch, Tracey, Mau-Sorensen, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946667/
https://www.ncbi.nlm.nih.gov/pubmed/33394101
http://dx.doi.org/10.1007/s00280-020-04180-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946667/
https://www.ncbi.nlm.nih.gov/pubmed/33394101
http://dx.doi.org/10.1007/s00280-020-04180-3

Ejemplares similares